THD Newsdesk, Hyderabad: Hyderabad-based pharma major Dr. Reddy’s Laboratories sealed its manufacturing services following an information breach in the servers, ET Now proclaimed.
The information infringement occurred at the company servers, and plants in the United States, United Kingdom, Brazil, India, and Russia were impacted.
“We are anticipating all services to be up within 24 hours, and we do not foresee any major impact on our operations due to this incident,” Dr. Reddy’s Chief Information Officer Muk Rathi announced.
Shares of the company fell as much as 4.3% on the news, dragging the Nifty pharma sub-index down 2%.
It occurred days after Dr. Reddy’s obtained approval from the Drug Controller General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for the Sputnik V vaccine in India.
The vaccine was developed by Russia’s Gamaleya Institute and financed by the Russian Development Investment Fund (RDIF). The multi-center and randomized controlled investigation, which will incorporate safety and immunogenicity study.
In September 2020, Dr. Reddy’s and RDIF subscribed to a partnership to conduct the Sputnik V vaccine’s clinical trials and India’s distribution. As part of the partnership, RDIF shall supply 100 million shots of the vaccine to Dr. Reddy’s administrative approval in India.
Sputnik V is currently executing the phase 3 clinical trial in Russia, and the intended number of subjects is 40,000. Additionally, phase 3 clinical trial of the vaccine commenced in the United Arab Emirates last week.
Dr. Reddy’s also has tie-ups with global firms to market coronavirus treatments remdesivir and favipiravir in India.
